Abstract:Background Globally, despite prostate cancer (PCa) representing second most prevalent malignancy in male, the precise molecular mechanisms implicated in its pathogenesis remain unclear. Consequently, elucidating the key molecular regulators that govern disease progression could substantially contribute to the establishment of novel therapeutic strategies, ultimately advancing the management of PCa. Methods A total of 49 PCa tissues and 43 adjacent normal tissues were collected from January 2017 to December 2021 at Zhongnan Hospital of Wuhan University. The advanced transcriptomic methodologies were employed to identify differentially expressed mRNAs in PCa. The expression of aspartoacylase (ASPA) in PCa was thoroughly evaluated using quantitative real-time PCR and Western blotting techniques. To elucidate the inhibitory role of ASPA in PCa cell proliferation and metastasis, a comprehensive set of in vitro and in vivo assays were conducted, including orthotopic and tumor-bearing mouse models ( n = 8 for each group). A combination of experimental approaches, such as Western blotting, luciferase assays, immunoprecipitation assays, mass spectrometry, glutathione S-transferase pull-down experiments, and rescue studies, were employed to investigate the underlying molecular mechanisms of ASPA’s action in PCa. The Student’s t -test was employed to assess the statistical significance between two distinct groups, while one-way analysis of variance was utilized for comparisons involving more than two groups. A two-sided P value of less than 0.05 was deemed to indicate statistical significance. Results ASPA was identified as a novel inhibitor of PCa progression. The expression of ASPA was found to be significantly down-regulated in PCa tissue samples, and its decreased expression was independently associated with patients’ prognosis ( HR = 0.60, 95% CI 0.40–0.92, P = 0.018). Our experiments demonstrated that modulation of ASPA activity, either through gain- or loss-of-function, led to the suppression or enhancement of PCa cell proliferation, migration, and invasion, respectively. The inhibitory role of ASPA in PCa was further confirmed using orthotopic and tumor-bearing mouse models. Mechanistically, ASPA was shown to directly interact with the LYN and inhibit the phosphorylation of LYN as well as its downstream targets, JNK1/2 and C-Jun, in both PCa cells and mouse models, in an enzyme-independent manner. Importantly, the inhibition of LYN activation by bafetinib abrogated the promoting effect of ASPA knockdown on PCa progression in both in vitro and in vivo models. Moreover, we observed an inverse relationship between ASPA expression and LYN activity in clinical PCa samples, suggesting a potential regulatory role of ASPA in modulating LYN signaling. Conclusion Our findings provide novel insights into the tumor-suppressive function of ASPA in PCa and highlight its potential as a prognostic biomarker and therapeutic target for the management of this malignancy.

Aspartoacylase promotes the process of tumour development and is associated with immune infiltrates in gastric cancer

Aspartoacylase Suppresses Prostate Cancer Progression by Blocking LYN Activation

Overexpression of the ASPM Gene is Associated with Aggressiveness and Poor Outcome in Bladder Cancer.

TASP1 Promotes Proliferation and Migration in Gastric Cancer via EMT and AKT/P-AKT Pathway

Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer

ASF1b is a Novel Prognostic Predictor Associated with Cell Cycle Signaling Pathway in Gastric Cancer

Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of β-catenin

Diverse Molecular Functions Of Aspartate Beta-Hydroxylase In Cancer

Aspartate Β-Hydroxylase Promotes Pancreatic Ductal Adenocarcinoma Metastasis Through Activation of SRC Signaling Pathway.

Overexpressed MAGP1 is Associated with a Poor Prognosis and Promotes Cell Migration and Invasion in Gastric Cancer

Prometastatic Secretome Trafficking Via Exosomes Initiates Pancreatic Cancer Pulmonary Metastasis.

Investigating MATN3 and ASPN as novel drivers of gastric cancer progression via EMT pathways

ASAP1 activates the IQGAP1/CDC42 pathway to promote tumor progression and chemotherapy resistance in gastric cancer

ASPM is a Novel Candidate Gene Associated with Colorectal Cancer Cell Growth

Prognostic and Immunological Role of Asporin Across Cancers and Exploration in Bladder Cancer.

ASPM promotes glioblastoma growth by regulating G1 restriction point progression and Wnt--catenin signaling

Aspartate β-hydroxylase as a target for cancer therapy

ASPM and TROAP gene expression as potential malignant tumor markers

Pan-cancer analysis of PSAP identifies its expression and clinical relevance in gastric cancer

Genome-wide analysis of the oxyntic proliferative isthmus zone reveals ASPM as a possible gastric stem/progenitor cell marker over-expressed in cancer

Asperuloside inhibits the activation of pancreatic cancer-associated fibroblasts via activating transcription factor 6